All In Biotech

Drug Trial Radar · NCT07734038

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Phase Two Study of Venetoclax Plus Zanubrutinib in Newly Diagnosed CLL and After Front-Line Time-Limited Venetoclax-Based Therapy

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

155

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Kerry RogersAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Giving venetoclax in combination with SOC zanubrutinib may be safe and tolerable and may reduce the number of cancer cells that remain in the body in patients with CLL or SLL that have not previously received treatment or at least two years have passed since completing initial treatment.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspiration

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • VenetoclaxDrug

    Given PO

  • ZanubrutinibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of undetectable minimal residual disease (uMRD) (Firstline Cohort)Time frame: At end of cycle 15 (cycle length = 28 days)
  2. Rate of uMRD (Second Line Cohort)Time frame: At end of cycle 27 (cycle length = 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.